Literature DB >> 11785573

FDA approval for a combined hepatitis A and B vaccine.

.   

Abstract

On May 11, 2001, the Food and Drug Administration (FDA) licensed a combined hepatitis A and B vaccine (Twinrix) for use in persons aged > or = 18 years. Twinrix is manufactured and distributed by GlaxoSmithKline Biologicals (Rixensart, Belgium), and is made of the antigenic components used in Havrix and Engerix-B (GlaxoSmithKline). The antigenic components in Twinrix have been used routinely in separate single antigen vaccines in the United States since 1995 and 1989 as hepatitis A and B vaccines, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11785573

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  Cost-effectiveness analysis of behavioral interventions to improve vaccination compliance in homeless adults.

Authors:  Barbara Greengold; Adeline Nyamathi; Gerald Kominski; Dorothy Wiley; Mary Ann Lewis; Felicia Hodge; Mendel Singer; Brennan Spiegel
Journal:  Vaccine       Date:  2008-11-27       Impact factor: 3.641

Review 2.  Combined hepatitis A and B vaccines: a review of their immunogenicity and tolerability.

Authors:  David L Murdoch; Karen Goa; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Recent Advances and New Challenges in Travel Medicine.

Authors:  Lin H. Chen; Mary E. Wilson
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

4.  Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases.

Authors:  Jiangan Xie; Lili Zhao; Shangbo Zhou; Yongqun He
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.